Repligen Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Repligen kazanç ve gelirin sırasıyla yıllık 51.4% ve 12.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 51.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

51.4%

Kazanç büyüme oranı

51.1%

EPS büyüme oranı

Life Sciences kazanç büyümesi	18.3%
Gelir büyüme oranı	12.9%
Gelecekteki özkaynak getirisi	4.9%
Analist kapsamı	Good
Son güncelleme	20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03

Recent updates

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Sep 08

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 31

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Jul 15

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:RGEN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	802	70	157	187	10
12/31/2025	697	47	102	162	15
12/31/2024	634	16	94	156	16
9/30/2024	634	-8	131	165	N/A
6/30/2024	620	9	119	155	N/A
3/31/2024	620	24	110	147	N/A
12/31/2023	632	36	75	114	N/A
9/30/2023	653	101	97	147	N/A
6/30/2023	712	124	51	149	N/A
3/31/2023	761	154	46	160	N/A
12/31/2022	802	186	39	172	N/A
9/30/2022	801	166	15	160	N/A
6/30/2022	779	159	41	141	N/A
3/31/2022	734	146	42	133	N/A
12/31/2021	671	128	48	119	N/A
9/30/2021	593	119	35	84	N/A
6/30/2021	509	100	40	83	N/A
3/31/2021	433	80	32	62	N/A
12/31/2020	366	60	36	63	N/A
9/30/2020	327	44	44	65	N/A
6/30/2020	302	31	42	66	N/A
3/31/2020	286	23	43	67	N/A
12/31/2019	270	21	44	67	N/A
9/30/2019	253	23	34	55	N/A
6/30/2019	233	27	34	53	N/A
3/31/2019	210	21	25	41	N/A
12/31/2018	194	17	19	33	N/A
9/30/2018	184	23	32	42	N/A
6/30/2018	171	23	N/A	21	N/A
3/31/2018	155	29	N/A	18	N/A
12/31/2017	141	28	N/A	17	N/A
9/30/2017	125	21	N/A	4	N/A
6/30/2017	113	18	N/A	5	N/A
3/31/2017	110	13	N/A	12	N/A
12/31/2016	105	12	N/A	8	N/A
9/30/2016	100	7	N/A	9	N/A
6/30/2016	96	8	N/A	17	N/A
3/31/2016	88	8	N/A	14	N/A
12/31/2015	84	9	N/A	15	N/A
9/30/2015	78	9	N/A	13	N/A
6/30/2015	74	8	N/A	13	N/A
3/31/2015	68	7	N/A	8	N/A
12/31/2014	64	8	N/A	18	N/A
9/30/2014	63	12	N/A	24	N/A
6/30/2014	66	16	N/A	24	N/A
3/31/2014	68	18	N/A	30	N/A
12/31/2013	68	16	N/A	26	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RGEN önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: RGEN önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: RGEN önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: RGEN şirketinin gelirinin (yıllık 12.9% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RGEN şirketinin gelirinin (yıllık 12.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RGEN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.9 %).

Repligen Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates increase by 10%

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 45%

Recent updates

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen Corporation to Report Q3, 2024 Results on Nov 12, 2024

Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Executive Chair recently sold US$1.8m worth of stock

Executive Chair notifies of intention to sell stock

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Insufficient new directors

Now 25% undervalued after recent price drop

Now 22% undervalued after recent price drop

Insider notifies of intention to sell stock

Insider recently sold US$740k worth of stock

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Tantti Laboratory Inc.

Now 20% undervalued after recent price drop

Repligen Corporation to Report Q2, 2024 Results on Jul 30, 2024

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Now 28% undervalued after recent price drop

Now 20% undervalued after recent price drop

Repligen Corporation Announces CEO Changes, Effective September 1, 2024

Repligen Corporation Announces Management Changes, Effective September 1, 2024

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Now 20% undervalued after recent price drop

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Repligen Stock: Still Quite Overvalued

CEO & Director recently sold US$3.4m worth of stock

CEO & Director notifies of intention to sell stock

Consensus EPS estimates increase by 10%

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024

New minor risk - Earnings quality

First quarter 2024 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation to Report Q1, 2024 Results on May 01, 2024

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen Corporation, Annual General Meeting, May 16, 2024

Repligen Corporation Appoints Maggie A. Pax as Board of Directors

CEO & Director recently sold US$3.3m worth of stock

CEO & Director notifies of intention to sell stock

Consensus EPS estimates fall by 45%

Chief Operating Officer recently sold US$680k worth of stock

Chief Operating Officer notifies of intention to sell stock

Price target increased by 8.2% to US$205

Repligen Corporation Provides Earnings Guidance for the Year 2024

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Repligen Corporation to Report Q4, 2023 Results on Feb 21, 2024

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Repligen Corporation announced that it has received $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Repligen Corporation announced that it expects to receive $290.1 million in funding

Insider recently sold US$557k worth of stock

Consensus EPS estimates increase by 16%

Repligen Corporation Launches TangenX®? SC as First-To-Market Holder-Free Self-Contained TFF Device

Price target decreased by 7.6% to US$179

Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Third quarter 2023 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 16%

Repligen Corporation to Report Q3, 2023 Results on Oct 31, 2023

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Repligen Corporation Appoints Olivier Loeillot as President and Chief Commercial Officer

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Metenova AB.